Search

Your search keyword '"Liu, Chia-Jen"' showing total 1,339 results
Start Over Author "Liu, Chia-Jen"
1,339 results on '"Liu, Chia-Jen"'

1. MP-PolarMask: A Faster and Finer Instance Segmentation for Concave Images

Author

Wang, Ke-Lei, Chou, Pin-Hsuan, Chou, Young-Ching, Liu, Chia-Jen, Lin, Cheng-Kuan, and Tseng, Yu-Chee

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

While there are a lot of models for instance segmentation, PolarMask stands out as a unique one that represents an object by a Polar coordinate system. With an anchor-box-free design and a single-stage framework that conducts detection and segmentation at one time, PolarMask is proved to be able to balance efficiency and accuracy. Hence, it can be easily connected with other downstream real-time applications. In this work, we observe that there are two deficiencies associated with PolarMask: (i) inability of representing concave objects and (ii) inefficiency in using ray regression. We propose MP-PolarMask (Multi-Point PolarMask) by taking advantage of multiple Polar systems. The main idea is to extend from one main Polar system to four auxiliary Polar systems, thus capable of representing more complicated convex-and-concave-mixed shapes. We validate MP-PolarMask on both general objects and food objects of the COCO dataset, and the results demonstrate significant improvement of 13.69% in AP_L and 7.23% in AP over PolarMask with 36 rays.

Published
2024

5. Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis

Author

Singhal, Udit, Nallandhighal, Srinivas, Tosoian, Jeffrey J., Hu, Kevin, Pham, Trinh M., Stangl-Kremser, Judith, Liu, Chia-Jen, Karim, Razeen, Plouffe, Komal R., Morgan, Todd M., Cieslik, Marcin, Lucianò, Roberta, Shariat, Shahrokh F., Finocchio, Nadia, Dambrosio, Lucia, Doglioni, Claudio, Chinnaiyan, Arul M., Tomlins, Scott A., Briganti, Alberto, Palapattu, Ganesh S., Udager, Aaron M., and Salami, Simpa S.

Published
2024
Full Text
View/download PDF

10. Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response

Author

Merrill, Nathan M., Kaffenberger, Samuel D., Bao, Liwei, Vandecan, Nathalie, Goo, Laura, Apfel, Athena, Cheng, Xu, Qin, Zhaoping, Liu, Chia-Jen, Bankhead, Armand, Wang, Yin, Kathawate, Varun, Tudrick, Lila, Serhan, Habib A., Farah, Zackariah, Ellimoottil, Chad, Hafez, Khaled S., Herrel, Lindsey A., Montgomery, Jeffrey S., Morgan, Todd M., Salami, Simpa S., Weizer, Alon Z., Ulintz, Peter J., Day, Mark L., Soellner, Matthew B., Palmbos, Phillip L., Merajver, Sofia D., and Udager, Aaron M.

Published
2024
Full Text
View/download PDF

12. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.

Author

Westbrook, Thomas C, Guan, Xiangnan, Rodansky, Eva, Flores, Diana, Liu, Chia Jen, Udager, Aaron M, Patel, Radhika A, Haffner, Michael C, Hu, Ya-Mei, Sun, Duanchen, Beer, Tomasz M, Foye, Adam, Aggarwal, Rahul, Quigley, David A, Youngren, Jack F, Ryan, Charles J, Gleave, Martin, Wang, Yuzhuo, Huang, Jiaoti, Coleman, Ilsa, Morrissey, Colm, Nelson, Peter S, Evans, Christopher P, Lara, Primo, Reiter, Robert E, Witte, Owen, Rettig, Matthew, Wong, Christopher K, Weinstein, Alana S, Uzunangelov, Vlado, Stuart, Josh M, Thomas, George V, Feng, Felix Y, Small, Eric J, Yates, Joel A, Xia, Zheng, and Alumkal, Joshi J

Subjects
Cell Line, Tumor, Humans, Benzamides, Nitriles, Phenylthiohydantoin, Receptors, Androgen, RNA, Biopsy, Drug Resistance, Neoplasm, Male, E2F1 Transcription Factor, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant, Prostate Cancer, Genetics, Urologic Diseases, Cancer, Clinical Research, 2.1 Biological and endogenous factors, Aetiology
Abstract

The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mechanisms have been described, including lineage plasticity in which the tumors manifest reduced dependency on the AR. To improve our understanding of enza resistance, herein we analyze the transcriptomes of matched biopsies from men with metastatic CRPC obtained prior to treatment and at progression (n = 21). RNA-sequencing analysis demonstrates that enza does not induce marked, sustained changes in the tumor transcriptome in most patients. However, three patients' progression biopsies show evidence of lineage plasticity. The transcription factor E2F1 and pathways linked to tumor stemness are highly activated in baseline biopsies from patients whose tumors undergo lineage plasticity. We find a gene signature enriched in these baseline biopsies that is strongly associated with poor survival in independent patient cohorts and with risk of castration-induced lineage plasticity in patient-derived xenograft models, suggesting that tumors harboring this gene expression program may be at particular risk for resistance mediated by lineage plasticity and poor outcomes.

Published
2022

14. Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in Taiwan

Author

Huang, Yi-Che, Hsiao, Fei-Yuan, Guan, Shang-Ting, Yao, Ming, Liu, Chia-Jen, Chen, Tzu-Ting, Lin, Tung-Liang, Liu, Yi-Chang, Chen, Tsai-Yun, Hong, Ying-Chung, Ma, Ming-Chun, Tan, Tran-Der, Wang, Chuan-Cheng, Wu, Yi-Ying, Liao, Po-Wei, Wu, Yi-Feng, Chen, Yi-Yang, Yu, Yuan-Bin, Hsieh, Yao-Yu, Lee, Ming-Yang, Liu, Jia-Hau, Lin, Shu-Wen, and Ko, Bor-Sheng

Published
2024
Full Text
View/download PDF

17. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.

Author

Salami, Simpa, Tosoian, Jeffrey, Nallandhighal, Srinivas, Jones, Tonye, Brockman, Scott, Elkhoury, Fuad, Bazzi, Selena, Plouffe, Komal, Siddiqui, Javed, Liu, Chia-Jen, Kunju, Lakshmi, Morgan, Todd, Natarajan, Shyam, Boonstra, Philip, Sumida, Lauren, Tomlins, Scott, Udager, Aaron, Sisk, Anthony, Marks, Leonard, and Palapattu, Ganesh

Subjects
Cancer progression, Gene fusions, Immunohistochemistry, Low-grade cancer, Next-generation sequencing, Prostate cancer, Tumor clonality, Cohort Studies, Humans, Image-Guided Biopsy, Longitudinal Studies, Male, Middle Aged, Neoplasm Grading, Prostate, Prostatic Neoplasms
Abstract

BACKGROUND: The potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear. OBJECTIVE: To interrogate the molecular and biological features of low-grade PCa serially over time. DESIGN, SETTING, AND PARTICIPANTS: Nested longitudinal cohort study in an academic active surveillance (AS) program. Men were on AS for GG1 PCa from 2012 to 2017. INTERVENTION: Electronic tracking and resampling of PCa using magnetic resonance imaging/ultrasound fusion biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ERG immunohistochemistry (IHC) and targeted DNA/RNA next-generation sequencing were performed on initial and repeat biopsies. Tumor clonality was assessed. Molecular data were compared between men who upgraded and those who did not upgrade to GG ≥ 2 cancer. RESULTS AND LIMITATIONS: Sixty-six men with median age 64 yr (interquartile range [IQR], 59-69) and prostate-specific antigen 4.9 ng/mL (IQR, 3.3-6.4) underwent repeat sampling of a tracked tumor focus (median interval, 11 mo; IQR, 6-13). IHC-based ERG fusion status was concordant at initial and repeat biopsies in 63 men (95% vs expected 50%, p

Published
2021

19. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer

Author

Cani, Andi K., Hu, Kevin, Liu, Chia-Jen, Siddiqui, Javed, Zheng, Yingye, Han, Sumin, Nallandhighal, Srinivas, Hovelson, Daniel H., Xiao, Lanbo, Pham, Trinh, Eyrich, Nicholas W., Zheng, Heng, Vince, Randy, Jr, Tosoian, Jeffrey J., Palapattu, Ganesh S., Morgan, Todd M., Wei, John T., Udager, Aaron M., Chinnaiyan, Arul M., Tomlins, Scott A., and Salami, Simpa S.

Published
2022
Full Text
View/download PDF

22. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature

Author

Nallandhighal, Srinivas, Vince, Randy, Karim, Razeen, Groves, Skylar, Stangl-Kremser, Judith, Russell, Christopher, Hu, Kevin, Pham, Trinh, Cani, Andi K., Liu, Chia-Jen, Zaslavsky, Alexander, Mehra, Rohit, Cieslik, Marcin, Morgan, Todd M., Palapattu, Ganesh S., Udager, Aaron M., and Salami, Simpa S.

Published
2022
Full Text
View/download PDF

28. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy

Author

Hovelson, Daniel H, Liu, Chia-Jen, Wang, Yugang, Kang, Qing, Henderson, James, Gursky, Amy, Brockman, Scott, Ramnath, Nithya, Krauss, John C, Talpaz, Moshe, Kandarpa, Malathi, Chugh, Rashmi, Tuck, Missy, Herman, Kirk, Grasso, Catherine S, Quist, Michael J, Feng, Felix Y, Haakenson, Christine, Langmore, John, Kamberov, Emmanuel, Tesmer, Tim, Husain, Hatim, Lonigro, Robert J, Robinson, Dan, Smith, David C, Alva, Ajjai S, Hussain, Maha H, Chinnaiyan, Arul M, Tewari, Muneesh, Mills, Ryan E, Morgan, Todd M, and Tomlins, Scott A

Subjects
Human Genome, Cancer, Prostate Cancer, Biotechnology, Genetics, Good Health and Well Being, cell-free DNA, precision oncology, prostate cancer, whole genome sequencing, copy-number analysis, Oncology and Carcinogenesis
Abstract

Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We sought to demonstrate the utility of a pan-cancer, rapid, inexpensive, whole genome NGS of cfDNA approach (PRINCe) as a precision oncology screening strategy via ultra-low coverage (~0.01x) tumor content determination through genome-wide copy number alteration (CNA) profiling. We applied PRINCe to a retrospective cohort of 124 cfDNA samples from 100 patients with advanced cancers, including 76 men with metastatic castration-resistant prostate cancer (mCRPC), enabling cfDNA tumor content approximation and actionable focal CNA detection, while facilitating concordance analyses between cfDNA and tissue-based NGS profiles and assessment of cfDNA alteration associations with mCRPC treatment outcomes. Therapeutically relevant focal CNAs were present in 42 (34%) cfDNA samples, including 36 of 93 (39%) mCRPC patient samples harboring AR amplification. PRINCe identified pre-treatment cfDNA CNA profiles facilitating disease monitoring. Combining PRINCe with routine targeted NGS of cfDNA enabled mutation and CNA assessment with coverages tuned to cfDNA tumor content. In mCRPC, genome-wide PRINCe cfDNA and matched tissue CNA profiles showed high concordance (median Pearson correlation = 0.87), and PRINCe detectable AR amplifications predicted reduced time on therapy, independent of therapy type (Kaplan-Meier log-rank test, chi-square = 24.9, p < 0.0001). Our screening approach enables robust, broadly applicable cfDNA-based precision oncology for patients with advanced cancer through scalable identification of therapeutically relevant CNAs and pre-/post-treatment genomic profiles, enabling cfDNA- or tissue-based precision oncology workflow optimization.

Published
2017

29. Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer

Author

Palapattu, Ganesh S, Salami, Simpa S, Cani, Andi K, Hovelson, Daniel H, de la Vega, Lorena Lazo, Vandenberg, Kelly R, Bratley, Jarred V, Liu, Chia-Jen, Kunju, Lakshmi P, Montgomery, Jeffery S, Morgan, Todd M, Natarajan, Shyam, Huang, Jiaoti, Tomlins, Scott A, and Marks, Leonard S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Genetics, Prostate Cancer, Urologic Diseases, Clinical Research, Cancer, Biomedical Imaging, Aging, Biotechnology, Aetiology, Detection, screening and diagnosis, 2.1 Biological and endogenous factors, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Aged, Biopsy, Clonal Evolution, High-Throughput Nucleotide Sequencing, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Neoplasm Grading, Neoplasm Proteins, Prostatic Neoplasms, Ultrasonography, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Purpose: To determine whether MRI/ultrasound (MRI/US) fusion biopsy facilitates longitudinal resampling of the same clonal focus of prostate cancer and to determine whether high-grade cancers can evolve from low-grade clones.Experimental Design: All men on active surveillance who underwent tracking MRI/US fusion biopsy of Gleason 6 prostate cancer, on at least two distinct occasions, between 2012 and 2014 were enrolled. MRI/US fusion was used to track and resample specific cancer foci. IHC for ERG and targeted RNA/DNA next-generation sequencing (NGS) were performed on formalin-fixed paraffin-embedded prostate biopsy specimens to assess clonality.Results: Thirty-one men with median age and PSA of 65 years and 4.6 ng/mL, respectively, were analyzed. The median sampling interval was 12 months (range, 5-35). Of the 26 evaluable men, ERG IHC concordance was found between initial and repeat biopsies in 25 (96%), indicating resampling of the same clonal focus over time. Targeted NGS supported ERG IHC results and identified unique and shared driving mutations, such as IDH1 and SPOP, in paired specimens. Of the nine men (34.6%) who were found to have Gleason ≥7 on repeat biopsy, all displayed temporal ERG concordance. Prioritized genetic alterations were detected in 50% (13/26) of paired samples. Oncogenic mutations were detected in 22% (2/9) of Gleason 6 cancers prior to progression and 44% (4/9) of Gleason ≥7 cancers when progression occurred.Conclusions: Precise tracking of prostate cancer foci via MRI/US fusion biopsy allowed subsequent resampling of the same clonal focus of cancer over time. Further research is needed to clarify the grade progression potential of Gleason 6 prostate cancer. Clin Cancer Res; 23(4); 985-91. ©2016 AACR.

Published
2017

31. Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study

Author

Lin, Chia-Hsin, Chou, Wen-Chi, Wu, Yao-Yu, Lin, Chien-Yu, Chang, Kai-Ping, Liao, Chun-Ta, Ho, Tsung-Ying, Yeh, Chiu-Mei, Liu, Chia-Jen, Hung, Sheng-Ping, Lee, Ching-Hsin, Chen, Po-Jui, Chou, Yung-Chih, Fan, Kang-Hsing, Huang, Bing-Shen, Tung-Chieh Chang, Joseph, Wang, Chun-Chieh, and Tsang, Ngan-Ming

Published
2021
Full Text
View/download PDF

37. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low‐risk patient as defined by targeted sequencing

Author

Tillman, Brittny N, Yanik, Megan, Birkeland, Andrew C, Liu, Chia-Jen, Hovelson, Daniel H, Cani, Andi K, Palanisamy, Nallasivam, Carskadon, Shannon, Carey, Thomas E, Bradford, Carol R, Tomlins, Scott A, McHugh, Jonathan B, Spector, Matthew E, and Brenner, J Chad

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Human Genome, Genetics, Rare Diseases, Clinical Research, Cancer, Dental/Oral and Craniofacial Disease, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Carcinoma, Squamous Cell, Class I Phosphatidylinositol 3-Kinases, DNA Copy Number Variations, DNA Mutational Analysis, Female, Fibroblast Growth Factors, Gene Expression Regulation, Neoplastic, Head and Neck Neoplasms, High-Throughput Nucleotide Sequencing, Humans, Middle Aged, Neoplasm Recurrence, Local, amplification, fibroblast growth factor, fibroblast growth factor receptor, head and neck squamous cell carcinoma, mutant, Dentistry, Otorhinolaryngology, Clinical sciences
Abstract

BackgroundTargeted sequencing of patients with epidemiologically low-risk (ELR) head and neck squamous cell carcinoma (HNSCC) could help identify novel drivers or lost suppressors leading to precision medicine protocols and improved survival rates.MethodsA patient with ELR-HNSCC was selected for targeted sequencing. We then assessed next generation sequencing cohorts from the Oncomine Powertool Database, which contains pan-cancer data from The Cancer Genome Atlas (TCGA).ResultsTargeted sequencing revealed fibroblast growth factor receptor-1 (FGFR1) amplifications as a putative driver of the patient's tumor. Patients with HNSCC from TCGA data demonstrated fibroblast growth factor (FGF) family mutations, rearrangements, or amplifications in over 35% of HNSCC cases, with a statistically significant higher frequency in African American populations. FGF alterations were unique from activating phosphatidylinositol 3-kinase (PIK3CA) mutations.ConclusionTogether, these data suggest that FGF signaling may be critical for a subset of patients with HNSCC independent of other known pathways and provides rationale for leveraging patients with ELR-HNSCC to define molecular subsets of high-risk HNSCC. © 2016 Wiley Periodicals, Inc. Head Neck 38: E1646-E1652, 2016.

Published
2016

38. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

Author

Zavidij, Oksana, Haradhvala, Nicholas J., Mouhieddine, Tarek H., Sklavenitis-Pistofidis, Romanos, Cai, Songjie, Reidy, Mairead, Rahmat, Mahshid, Flaifel, Abdallah, Ferland, Benjamin, Su, Nang K., Agius, Michael P., Park, Jihye, Manier, Salomon, Bustoros, Mark, Huynh, Daisy, Capelletti, Marzia, Berrios, Brianna, Liu, Chia-Jen, He, Meng Xiao, Braggio, Esteban, Fonseca, Rafael, Maruvka, Yosef E., Guerriero, Jennifer L., Goldman, Melissa, Van Allen, Eliezer M., McCarroll, Steven A., Azzi, Jamil, Getz, Gad, and Ghobrial, Irene M.

Published
2020
Full Text
View/download PDF

39. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma

Author

Nassar, Amin H., Mouw, Kent W., Jegede, Opeyemi, Shinagare, Atul B., Kim, Jaegil, Liu, Chia-Jen, Pomerantz, Mark, Harshman, Lauren C., Van Allen, Eliezer M., Wei, Xiao X., McGregor, Bradley, Choudhury, Atish D., Preston, Mark A., Dong, Fei, Signoretti, Sabina, Lindeman, Neal I., Bellmunt, Joaquim, Choueiri, Toni K., Sonpavde, Guru, and Kwiatkowski, David J.

Published
2020
Full Text
View/download PDF

40. Secondary Primary Malignancy Risk in Patients With Cervical Cancer in Taiwan

Author

Teng, Chung-Jen, Huon, Leh-Kiong, Hu, Yu-Wen, Yeh, Chiu-Mei, Chao, Yee, Yang, Muh-Hwa, Chen, Tzeng-Ji, Hung, Yi-Ping, and Liu, Chia-Jen

Subjects
Patient Safety, Health Services, Cervical Cancer, Cancer, Clinical Research, Adult, Aged, Antineoplastic Agents, Carboplatin, Comorbidity, Female, Fluorouracil, Humans, Middle Aged, Neoplasms, Second Primary, Radiotherapy, Registries, Taiwan, Uterine Cervical Neoplasms, Young Adult, Clinical Sciences, Arthritis & Rheumatology
Abstract

To evaluate the risk of secondary primary malignancy (SPM) in patients with cervical cancer using a nationwide population-based dataset.Patients newly diagnosed with cervical cancer between 1997 and 2011 were identified using Taiwan's National Health Insurance database. Patients with antecedent malignancies were excluded. Standardized incidence ratios (SIRs) for SPM were calculated by comparing with the cancer incidence in the general population. Risk factors for cancer development were analyzed using Cox proportional hazard models.During the 14-year study period (follow-up of 223,062 person-years), 2004 cancers developed in 35,175 patients with cervical cancer. The SIR for all cancers was 1.56 (95% confidence interval, 1.50-1.63, P 10, 5 to 10, 1 to 5, and

Published
2015

41. Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan

Author

Hung, Yi-Ping, Liu, Chia-Jen, Hu, Yu-Wen, Chen, Min-Huang, Li, Chun-Pin, Yeh, Chiu-Mei, Chiou, Tzeon-Jye, Chen, Tzeng-Ji, Yang, Muh-Hwa, and Chao, Yee

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Ovarian Cancer, Rare Diseases, Cancer, Clinical Research, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Comorbidity, Female, Fluorouracil, Humans, Incidence, Middle Aged, Neoplasms, Second Primary, Ovarian Neoplasms, Radiotherapy, Retrospective Studies, Risk Assessment, Taiwan, Young Adult
Abstract

To evaluate the incidence of secondary primary malignancy (SPM) in patients with ovarian cancer using a nationwide retrospective population-based dataset. Patients newly diagnosed with ovarian cancer between 1997 and 2010 were identified using Taiwan's National Health Insurance database. Patients with antecedent malignancies were excluded. Standardized incidence ratios (SIRs) for SPM were calculated and compared with the cancer incidence in the general population. Risk factors for cancer development were analyzed using Cox proportional hazard models. Effects of surgery, chemotherapy, and radiotherapy after ovarian cancer diagnosis were regarded as time-dependent variables to prevent immortal time bias. During the 14-year study period (follow-up of 56,214 person-years), 707 cancers developed in 12,127 patients with ovarian cancer. The SIR for all cancers was 2.78 (95% confidence interval 2.58-3.00). SIRs for follow-up periods of >5, 1-5, and

Published
2015

47. Precision Medicine-Based Platform to Guide the Treatment of EML4-ALK Lung Cancers and Other Non-Small Cell Lung Cancers

Author

Merrill, Nathan, primary, Udager, Aaron, additional, Qin, Angel, additional, Lagisetty, Kiran, additional, Aikins, Marisa, additional, Bao, Liwei, additional, Cheng, Xu, additional, Goo, Layra, additional, Kathawate, Varun, additional, Vandenburg, Bryce, additional, Ulintz, Peter, additional, Qin, Zhaoping, additional, Liu, Chia-Jen, additional, Serhan, Habib, additional, Nagrath, Sunitha, additional, Hsu, Peggy, additional, Soellner, Matthew, additional, and Merajver, Sofia, additional

Published
2023
Full Text
View/download PDF

50. FRI137 Histologic And Genetic Characteristics Of Primary Aldosteronism In Late Adulthood

Author

Blinder, Amy, primary, Nanba, Kazutaka, additional, Sapiro, Dina, additional, Baker, Jessica, additional, Liu, Chia-Jen, additional, Bancos, Irina, additional, Lyden, Melanie, additional, Young, William, additional, Wachtel, Heather, additional, Cohen, Debbie, additional, Luther, James, additional, Ann Williams, Tracy, additional, Reincke, Martin, additional, Else, Tobias, additional, Giordano, Thomas J, additional, Udager, Aaron, additional, and Rainey, William E, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results